Voyager Therapeutics, Inc. financial data

Symbol
VYGR on Nasdaq
Location
75 Hayden Avenue, Lexington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 579 % -13.6%
Debt-to-equity 30.9 % -12.7%
Return On Equity -48.9 % -688%
Return On Assets -37.4 % -708%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.6M shares +1.78%
Common Stock, Shares, Outstanding 55.5M shares +1.72%
Entity Public Float 408M USD -16.6%
Common Stock, Value, Issued 56K USD +1.82%
Weighted Average Number of Shares Outstanding, Basic 58.8M shares +1.65%
Weighted Average Number of Shares Outstanding, Diluted 58.8M shares +1.65%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 31.3M USD -80.9%
Research and Development Expense 134M USD +14.3%
General and Administrative Expense 37.2M USD +0.15%
Operating Income (Loss) -140M USD -1645%
Nonoperating Income (Expense) 14.1M USD -20.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -126M USD -571%
Income Tax Expense (Benefit) 719K USD -20.4%
Net Income (Loss) Attributable to Parent -127M USD -590%
Earnings Per Share, Basic -2 USD/shares -466%
Earnings Per Share, Diluted -2 USD/shares -466%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.1M USD -59.9%
Marketable Securities, Current 164M USD -29.6%
Cash, Cash Equivalents, and Short-term Investments 229M USD -33.7%
Other Assets, Current 2.87M USD +9.36%
Assets, Current 220M USD -41.2%
Property, Plant and Equipment, Net 13.3M USD -12.6%
Operating Lease, Right-of-Use Asset 29.7M USD -13.9%
Assets 288M USD -32.3%
Accounts Payable, Current 2.12M USD -33%
Employee-related Liabilities, Current 6.22M USD +4.91%
Accrued Liabilities, Current 15M USD +30.7%
Contract with Customer, Liability, Current 10.6M USD -53.3%
Liabilities, Current 35.5M USD -19.7%
Contract with Customer, Liability, Noncurrent 1.47M USD -87.9%
Operating Lease, Liability, Noncurrent 30.5M USD -20.5%
Other Liabilities, Noncurrent 37.5M USD +107%
Liabilities 68.5M USD -28.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 7K USD
Retained Earnings (Accumulated Deficit) -418M USD -43.5%
Stockholders' Equity Attributable to Parent 220M USD -33.4%
Liabilities and Equity 288M USD -32.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.9M USD -164%
Net Cash Provided by (Used in) Financing Activities 82K USD -99.9%
Net Cash Provided by (Used in) Investing Activities 41.2M USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 55.5M shares +1.72%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.39M USD -95.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 50.7M USD -56%
Deferred Tax Assets, Valuation Allowance 106M USD +28.1%
Deferred Tax Assets, Gross 118M USD +32.2%
Operating Lease, Liability 38.4M USD
Depreciation 1.01M USD -15.2%
Payments to Acquire Property, Plant, and Equipment 658K USD -69.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -127M USD -586%
Lessee, Operating Lease, Liability, to be Paid 45.2M USD
Property, Plant and Equipment, Gross 30.3M USD -4%
Operating Lease, Liability, Current 7.85M USD +12.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.76M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 9.98M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.81M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 8M USD
Deferred Tax Assets, Operating Loss Carryforwards 4.24M USD -69.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.24M USD
Additional Paid in Capital 638M USD +2.61%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 11.9M USD +84.5%
Share-based Payment Arrangement, Expense 15M USD +6.44%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%